Mayne Renews Crusade For Colon Cancer Drug
The suit, filed Wednesday in the eastern Virginia district court, contends that one of the patents that cover Sanofi's oxiplatin formulations and manufacturing processes—6,306,902—is invalid and unenforceable and therefore is not infringed by any of Mayne's actions. It seeks declaratory judgment saying as much.
According to the complaint, the '902 patent is the U.S....
To view the full article, register now.